Bluejay Diagnostics recently priced a firm commitment underwritten public offering. Aegis Capital Corp led the planning. The funds expected to be generated are ~USD 8.75 million (gross).
The funds will be used to repay an outstanding debt of USD 2.3 million and other various pursuits, including FDA approvals, clinical studies, other R&D activities, and general working capital requirements.
Bluejay Diagnostics is a medical diagnostics company specializing in rapid, near-patient testing systems to improve patient outcomes in critical care settings. The company's flagship Symphony System product facilitates whole-blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force. Its primary product candidate, the IL-6 test for sepsis triage, supports medical decision-making. Bluejay also offers the ALLEREYE diagnostic test for allergic conjunctivitis and is developing cardiac biomarkers such as hsTNT and NT pro-BNP.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.